Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone913-353-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$35.41 million
Profitability
Miscellaneous
Employees83
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable
Aratana Therapeutics (NASDAQ:PETX) Frequently Asked Questions
What is Aratana Therapeutics' stock symbol?
Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX."
How were Aratana Therapeutics' earnings last quarter?
Aratana Therapeutics Inc (NASDAQ:PETX) released its earnings results on Thursday, November, 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.03. The biopharmaceutical company earned $21.56 million during the quarter, compared to analysts' expectations of $5.70 million. Aratana Therapeutics had a negative net margin of 33.47% and a negative return on equity of 12.99%. View Aratana Therapeutics' Earnings History.
When is Aratana Therapeutics' next earnings date?
What price target have analysts set for PETX?
4 equities research analysts have issued 12-month price objectives for Aratana Therapeutics' shares. Their predictions range from $4.14 to $5.00. On average, they expect Aratana Therapeutics' stock price to reach $4.73 in the next year. View Analyst Price Targets for Aratana Therapeutics.
What is the consensus analysts' recommendation for Aratana Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aratana Therapeutics in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aratana Therapeutics.
Has Aratana Therapeutics been receiving favorable news coverage?
Press coverage about PETX stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aratana Therapeutics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Aratana Therapeutics.
Who are some of Aratana Therapeutics' key competitors?
Some companies that are related to Aratana Therapeutics include Epizyme (EPZM), Y-mAbs Therapeutics (YMAB), Spectrum Pharmaceuticals (SPPI), ANI Pharmaceuticals (ANIP), Amneal Pharmaceuticals (AMRX), Odonate Therapeutics (ODT), TherapeuticsMD (TXMD), Phibro Animal Health (PAHC), Eagle Pharmaceuticals (EGRX), Achillion Pharmaceuticals (ACHN), ZEALAND PHARMA/S (ZEAL), G1 Therapeutics (GTHX), Dova Pharmaceuticals (DOVA), Athenex (ATNX) and Rhythm Pharmaceuticals (RYTM).
What other stocks do shareholders of Aratana Therapeutics own?
Who are Aratana Therapeutics' key executives?
Aratana Therapeutics' management team includes the folowing people:
- Mr. Craig A. Tooman, Pres, CEO & Board Director (Age 53)
- Ms. Rhonda L. Hellums, CFO & Treasurer (Age 47)
- Mr. John C. Ayres J.D., VP of Corp. Devel. and Admin., Gen. Counsel & Sec. (Age 40)
- Mr. Brent A. Standridge, Consultant (Age 61)
- Ms. Rachel Reiff, Head of Corp. Communications
How big of a company is Aratana Therapeutics?
Aratana Therapeutics has a market capitalization of $0.00 and generates $35.41 million in revenue each year. The biopharmaceutical company earns $-14,720,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Aratana Therapeutics employs 83 workers across the globe.View Additional Information About Aratana Therapeutics.
What is Aratana Therapeutics' official website?
How can I contact Aratana Therapeutics?
Aratana Therapeutics' mailing address is 11400 TOMAHAWK CREEK PARKWAY SUITE 340, LEAWOOD KS, 66211. The biopharmaceutical company can be reached via phone at 913-353-1000 or via email at [email protected]
MarketBeat Community Rating for Aratana Therapeutics (NASDAQ PETX)
MarketBeat's community ratings are surveys of what our community members think about Aratana Therapeutics and other stocks. Vote "Outperform" if you believe PETX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PETX will underperform the S&P 500 over the long term. You may vote once every thirty days.
